While further research is needed, our findings suggest that it may be beneficial to use erlotinib, a relatively non-toxic targeted agent, to initially treat patients with advanced lung cancer, rather than use conventional chemotherapy regimens.

-Bruce Johnson

Select a background
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image
Awesome background image

More quotes by Bruce Johnson